Abstract
Next generation vaccines
Highlights
Background and aimsThere is a need for broadly protective pneumococcal vaccines that are affordable for developing countries where the highest burden of pneumococcal disease occurs
We test in different animal models the efficacy of a variety of multivalent vaccines comprising one or more of the following antigens: pneumolysin toxoid (L460D); L460D fused with protective peptide epitopes from choline-binding protein A (CbpA) (YPT-L460D-NEEK [YLN]); L460D fused with peptide CD2 containing the proline-rich region (PRR) of pneumococcal surface protein A (PspA) (CD2-L460D); L460D + H70, a slightly larger PspA-derived peptide containing the PRR and the SM1 region; H70+YLN, and other combinations
We have developed a conjugate vaccine in which PspA, a protein common to all Streptococcus pneumonia was conjugated to Vi capsular polysaccharide from Salmonella typhi
Summary
Background and aimsThere is a need for broadly protective pneumococcal vaccines that are affordable for developing countries where the highest burden of pneumococcal disease occurs. Methods: Immune responses measured by pneumococcal serotype-specific ELISA and opsonophagocytic activity (OPA) assays, one month after 3-dose primary vaccination with PHiD-CV, were assessed in several randomized controlled trials conducted across different geographic regions. Conclusion: Our results demonstrated that the different vaccine preparations displayed comparable protective properties These results support the continuous process with cell recycle as a strategy for large scale WCV production for human immunization. Results: Mouse immunization with the recombinant proteins induced the production of specific antibodies against rPotD, while a significant increase in cytokine and NO was observed in peritoneal and spleen cells after stimulation with rPotD and rPdT. New generation ®PRINT nanoparticle Pneumococcal vaccine aims to harness key pathogen associated molecular features that can be mimicked for B/T-cell targeting to induce potent antigen-specific immune responses. Conclusion: The DNA vaccine based on T-Cell epitopes from almost all the PspA variants may prove to be immunogenic and provide protection against S. pneumoniae infection
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
